Scibase AB
The answer first
Does Scibase beat the market?
No, Scibase has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 1% of Nordic stocks
- Quality16
- Value17
- Trend5
No. 190 of 195 in healthcare
Max for seven days
Follow Scibase with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Scibase
Your first answer is free, no account needed.
Do you own Scibase, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Scibase and a few more. Free, no card.
Super Stock+44.6%In short
- Scibase has fallen 56.5% over the past year, including dividends.
- Overall, Scibase ranks better than 1% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 96.4%. The price is 99.6% below its peak now.
What do analysts think of Scibase?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 1% of Nordic stocks.
No. 190 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 176 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.80
- Asset turnoverSales divided by everything the company owns1.06
- Return on equityProfit divided by equity−322.7%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 110 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity16.3
- P/SPrice divided by sales1.6
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 172 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−56.5%
- 6 months−79.2%
- 9 months−63.7%
- 12 months−56.5%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
About Scibase
Scibase AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 46 employees.
SciBase Holding AB (publ), a medical technology company, develops and commercializes point-of-care platforms for skin health management in Europe, the United States, North America, Asia, Oceania, and internationally. It operates through Skin Cancer and Skin Barrier Assessment segments. The company offers Nevisense and Nevisense Go point-of-care platforms to detect melanoma and non-melanoma skin cancer; and for research within skin barrier assessment. It has a collaboration with Mayo Clinic on pigmented lesion digital workflows with AI-driven Nevisense.SciBase Holding AB (publ) was founded in 1998 and is headquartered in Sundbyberg, Sweden.


See the full analysis of Scibase.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card